Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast...

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to its aggressive characteristics and absence of hormone receptor and HER2 expression.
• Current treatment paradigms for TNBC are evolving with the advent of novel therapeutic agents.

Purpose of the Study:

• To summarize recent advancements in antibody-drug conjugates (ADCs) and immunotherapy combinations for TNBC.
• To discuss the synergistic mechanisms underlying these combined therapeutic strategies.
• To provide insights into future personalized therapeutic approaches for TNBC.

Main Methods:

• Review of recent clinical trials and research investigating ADCs (e.g., sacituzumab govitecan, datopotamab deruxtecan) in TNBC.
• Analysis of studies combining ADCs with immune checkpoint inhibitors.
• Evaluation of treatment efficacy in metastatic, neoadjuvant, and adjuvant settings.

Main Results:

• ADCs have demonstrated superior efficacy compared to standard chemotherapy in metastatic TNBC.
• Combinations of ADCs and immune checkpoint inhibitors show enhanced antitumor activity in ongoing clinical trials (e.g., MORPHEUS-panBC, BEGONIA).
• These novel combinations are being actively explored in early-stage TNBC treatment settings.

Conclusions:

• ADCs and immunotherapy combinations represent a significant therapeutic advance for TNBC.
• Understanding synergistic mechanisms is crucial for optimizing treatment strategies.
• Future research should focus on personalized therapeutic approaches to improve outcomes for TNBC patients.